Plasma cell leukemia

Blood Reviews

Volumn 25, Issue 3, 2011, Pages 107-112

  Albarracin, Flavio ^a   Fonseca, Rafael ^b  

^a Hospital Central Mendoza   (Argentina)

^b MAYO CLINIC   (United States)

Author keywords

Plasma cell leukemia

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PREDNISONE; PROTEIN P53; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SMEAR; BONE ATROPHY; BONE MARROW BIOPSY; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE INACTIVATION; GENE MUTATION; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; IMMUNOPHENOTYPING; KIDNEY FAILURE; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ELECTROPHORESIS; SPLENOMEGALY; STEM CELL MOBILIZATION; THROMBOCYTOPENIA;

AGED; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, PLASMA CELL; MALE; MULTIPLE MYELOMA; SURVIVAL ANALYSIS;

EID: 79953169444     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2011.01.005     Document Type: Article

References (53)

1. Kyle R.A., Maldonado J.E., Bayrd E.D. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974, 133:813-818.
2. Noel P., Kyle R.A. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987, 83:1062-1068.
3. Criteria for the classification of monoclonal gammopathies multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757.
4. Blade J., Kyle R.A. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999, 13:1259-1272.
5. Jimenez-Zepeda V.H., Dominguez V.J. Plasma cell leukemia: a rare condition. Ann Hematol 2006, 85:263-267.
6. Yamamoto J.F., Goodman M.T. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008, 19:379-390.
7. Tiedemann R.E., Gonzalez-Paz N., Kyle R.A., et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008, 22:1044-1052.
8. Garcia-Sanz R., Orfao A., Gonzalez M., et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999, 93:1032-1037.
9. San Miguel J.F., Gonzalez M., Gascon A., et al. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1991, 77:185-190.
10. Hayman S.R., Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol 2001, 2:205-216.
11. Pellat-Deceunynck C., Bataille R., Robillard N., et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994, 84:2597-2603.
12. Avet-Loiseau H., Daviet A., Brigaudeau C., et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001, 97:822-825.
13. Taniwaki M., Nishida K., Ueda Y., Takashima T. Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. Leuk Lymphoma 1996, 21:25-30.
14. Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
15. Chang H., Qi X.Y., Samiee S., et al. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005, 36:793-796.
16. Hanamura I., Stewart J.P., Huang Y., et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006, 108:1724-1732.
17. Chang H., Qi X., Trieu Y., et al. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006, 135:486-491.
18. Fonseca R., Van Wier S.A., Chng W.J., et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006, 20:2034-2040.
19. Shaughnessy J.D., Zhan F., Burington B.E., et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109:2276-2284.
20. Chang H., Ning Y., Qi X., Yeung J., Xu W. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. Br J Haematol 2007, 139:51-54.
21. Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
22. Chang H., Qi X., Yeung J., Reece D., Xu W., Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009, 33:259-262.
23. Fonseca R., Blood E., Rue M., et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101:4569-4575.
24. Chng W.J., Price-Troska T., Gonzalez-Paz N., et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007, 21:582-584.
25. Lloveras E., Granada I., Zamora L., et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet Cytogenet 2004, 148:71-76.
26. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
27. Stott F.J., Bates S., James M.C., et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998, 17:5001-5014.
28. Eymin B., Gazzeri S., Brambilla C., Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002, 21:2750-2761.
29. Esteller M., Cordon-Cardo C., Corn P.G., et al. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001, 61:2816-2821.
30. Magdinier F., Wolffe A.P. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA 2001, 98:4990-4995.
31. Ahuja H.G., Foti A., Bar-Eli M., Cline M.J. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990, 75:1684-1690.
32. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001, 18:212-224.
33. Ortega M.M., Faria R.M., Shitara E.S., et al. N-RAS and K-RAS gene mutations in Brazilian patients with multiple myeloma. Leuk Lymphoma 2006, 47:285-289.
34. Liang D.C., Shih L.Y., Fu J.F., et al. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer 2006, 106:950-956.
35. Fonseca R., Witzig T.E., Gertz M.A., et al. Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. Br J Haematol 1998, 101:296-301.
36. Lai J.L., Michaux L., Dastugue N., et al. Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant. Cancer Genet Cytogenet 1998, 104:133-138.
37. Dimopoulos M.A., Palumbo A., Delasalle K.B., Alexanian R. Primary plasma cell leukaemia. Br J Haematol 1994, 88:754-759.
38. Musto P., Rossini F., Gay F., et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007, 109:2285-2290.
39. Benson D.M., Smith M.K. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 2007, 48:1423-1425.
40. Musto P., Pietrantuono G., Guariglia R., et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008, 32:1637-1638.
41. Johnston R.E., Abdalla S.H. Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk Lymphoma 2002, 43:351-354.
42. Tsiara S., Chaidos A., Kapsali H., Tzouvara E., Bourantas K.L. Thalidomide administration for the treatment of resistant plasma cell leukemia. Acta Haematol 2003, 109:153-155.
43. Wohrer S., Ackermann J., Baldia C., et al. Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report. Hematol J 2004, 5:361-363.
44. Bauduer F. Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. Br J Haematol 2002, 117:996-997.
45. Guglielmelli T., Merlini R., Giugliano E., Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol 2009, 2009:867380.
46. Esparis-Ogando A., Alegre A., Aguado B., et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005, 114:665-667.
47. Finnegan D.P., Kettle P., Drake M., et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006, 47:1670-1673.
48. Grassinger J., Sudhoff T., Andreesen R., Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006, 85:132-133.
49. Katodritou E., Verrou E., Gastari V., Hadjiaggelidou C., Terpos E., Zervas K. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leuk Res 2008, 32:1153-1156.
50. Al-Nawakil C., Tamburini J., Bardet V., et al. Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leuk Lymphoma 2008, 49:2012-2014.
51. Chan S.M., George T., Cherry A.M., Medeiros B.C. Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. Cases J 2009, 2:121.
52. Saccaro S., Fonseca R., Veillon D.M., et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005, 78:288-294.
53. Mahindra A., Vesole D., Kalaycio M., et al. Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience. Blood 2009, 114:22. [abstract 532], ASH Annual Meeting Abstracts.